Immunic (STU:10VA) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Immunic Debt-to-Equity?

Immunic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.64 Mil. Immunic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.40 Mil. Immunic's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €76.89 Mil. Immunic's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Immunic's Debt-to-Equity or its related term are showing as below:

STU:10VA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.05
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Immunic was 0.05. The lowest was 0.01. And the median was 0.01.

STU:10VA's Debt-to-Equity is ranked better than
99.91% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs STU:10VA: 0.01

Immunic Debt-to-Equity Historical Data

The historical data trend for Immunic's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Debt-to-Equity Chart

Immunic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.05

Immunic Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.03	0.03	0.05	0.01

Competitive Comparison of Immunic's Debt-to-Equity

For the Biotechnology subindustry, Immunic's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunic's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Immunic's Debt-to-Equity falls into.

Immunic Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Immunic's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.637	+	0.586)	/	26.53
	=	0.05

Immunic's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.641	+	0.398)	/	76.89
	=	0.01

Immunic (STU:10VA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Immunic Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Immunic's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (STU:10VA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IMUX:USA 10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines